Mycomycen (Ciclopirox Olamine)

Ciclopirox olamine acts by chelating polyvalent metal ions, which interferes with fungal sterol synthesis and disrupts essential membrane transport processes. This loss of cellular homeostasis leads to fungal cell death, providing a broad‑spectrum antifungal effect without affecting human cells.

The dosage and duration of Mycomycen are determined by the prescribing healthcare professional based on the severity of the infection and patient factors. Typically, the product is applied intravaginally as directed on the label or by a clinician, and patients should follow the exact instructions provided.

Safety data for ciclopirox olamine in pregnancy and lactation are limited. Use Mycomycen only if the potential benefit justifies any possible risk to the fetus or infant, and always discuss use with a qualified healthcare provider before starting therapy.

To place an order, submit an enquiry on the Mycomycen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mycomycen (ciclopirox olamine) offers a non‑azole mechanism of action, which can be advantageous for patients with azole‑resistant Candida strains. Compared with azole agents, it is applied locally, has minimal systemic absorption, and may have a different side‑effect profile, making it a useful alternative in certain clinical scenarios.

Store Mycomycen at room temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain stability and potency.

Mycomycen is administered intravaginally. The prescribed amount is applied directly into the vagina using the supplied applicator or as instructed by a healthcare professional. Patients should follow the dosing schedule on the label or as directed by their prescriber for optimal effectiveness.

The most serious risks include severe allergic reactions such as swelling, hives, or difficulty breathing, and rare cases of ulcerative lesions or secondary bacterial infection. If any signs of a serious reaction occur, discontinue use immediately and seek medical attention.

Mycomycen should not be used by individuals with a known hypersensitivity to ciclopirox olamine or any component of the formulation. Patients with active severe vaginal infections of bacterial origin should consult a clinician before use, and it is contraindicated in those with documented allergic reactions to similar antifungal agents.